HRTX Opioid-Free Pain Med Candidate Continues to Impress


Yesterday, Heron (HRTX) reported additional data for its opioid-free pain med candidate HTX-011 in a post-surgery setting. In the latest report-out 77% of bunionectomy patients remained opioid-free 72 hours post surgery when HTX-011 was administered with over-the-counter pain meds in the latest extension study from their prior successful Phase 3 program. Earlier this year, HRTX reported additional extension study data from a hernia repair study where 90% of patients were opioid free 72 hours post surgery with the combination of HTX-011 plus over-the-counter meds.

HTX-011 is under priority review by the FDA with a target PDUFA data of April 30, 2018. HRTX has been lagging the stock price run up of many small/mid biopharma companies this year. Its current market cap of about $2 billion seems attractive given the potential market for HRTX and prior clinical results. Of course, there is always risk with a PDUFA review related to manufacturing and quality control. If the FDA approves HTX-011 and gives it a broad label related to post-operative surgery, investors could be rewarded in the near-term. Either way, HTX-011 appears to be an important future pain med in the fight against the current opioid epidemic.

https://herontherapeutics.gcs-web.com/news-releases/news-release-details/77-patients-remain-opioid-free-when-htx-011-given-over-counter

#AmpFree #HRTX #Q119 #Q219 #nonopioid

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon